Actionable news
All posts from Actionable news
Actionable news in JUNO: JUNO THERAPEUTICS Inc,

Juno Therapeutics Rebound Will Continue, Vetr Crowd Says

2016 wasn't especially kind to Juno Therapeutics Inc JUNO 0.12% stock. Shares of the small cap biopharmaceutical have lost more than 25 percent of their value year-to-date.

Nonetheless, over the past month, the stock staged a rebound, recuperating more than 12.6 percent. The Vetr crowd seems to believe the rally will continue, as evidenced by its average price target of $38.02, which implies a potential return of roughly 16 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Juno on Monday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.

It should be noted that, in accordance with the new rating, 84 percent of the crowd’s ratings are bullish.

Jul 2016BarclaysInitiates Coverage onEqual-weight
Jun 2016Raymond JamesInitiates Coverage onOutperform
May 2016Cowen & CompanyInitiates Coverage onOutperform

© 2016 Benzinga does not provide investment advice. All rights reserved.